Introduction: Transient ischaemic attack (TIA) may be a warning sign of stroke and difficult to differentiate from minor stroke and TIA-mimics. Urgent evaluation and diagnosis is important as treating TIA early can prevent subsequent strokes. Recent improvements in mass spectrometer technology allow quantification of hundreds of plasma proteins and lipids, yielding large datasets that would benefit from different approaches including machine learning. Using plasma protein, lipid and radiological biomarkers, our study will develop predictive algorithms to distinguish TIA from minor stroke (positive control) and TIA-mimics (negative control). Analysis including machine learning employs more sophisticated modelling, allowing non-linear interactions, adapting to datasets and enabling development of multiple specialised test-panels for identification and differentiation. Methods and analysis: Patients attending the Emergency Department, Stroke Ward or TIA Clinic at the Royal Adelaide Hospital with TIA, minor stroke or TIA-like symptoms will be recruited consecutively by staff-alert for this prospective cohort study. Advanced neuroimaging will be performed for each participant, with images assessed independently by up to three expert neurologists. Venous blood samples will be collected within 48 hours of symptom onset. Plasma proteomic and lipid analysis will use advanced mass spectrometry (MS) techniques. Principal component analysis and hierarchical cluster analysis will be performed using MS software. Output files will be analysed for relative biomarker quantitative differences between the three groups. Differences will be assessed by linear regression, one-way analysis of variance, Kruskal-Wallis H-test, χ 2 test or Fisher’s exact test. Machine learning methods will also be applied including deep learning using neural networks. Ethics and dissemination: Patients will provide written informed consent to participate in this grant-funded study. The Central Adelaide Local Health Network Human Research Ethics Committee approved this study (HREC/18/CALHN/384; R20180618). Findings will be disseminated through peer-reviewed publication and conferences; data will be managed according to our Data Management Plan (DMP2020-00062).
We have developed a novel biosensing device that can detect the real-time, dynamic state of in vivo oxidative status (IVOS) in living systems. Oxidative stress is a well-established condition in CF animal models and humans. Elevated oxidative stress conditions are associated with excessive inflammatory responses from neutrophils that result in fibrotic tissue formation. As such, numerous clinical and preclinical studies suggest that elevated oxidative stress, combined with the heightened pro-inflammatory milieu observed in CF phenotypes, likely increases susceptibility to recurrent infection–inflammation cycles. We aimed to use the IVOS sensor to characterise oxidative environmental differences in wildtype, CF Phe508del and CFTR knockout rat epithelial tissues including the lungs, trachea, nasal mucosa, and oesophagus. Our results revealed no significant differences in the baseline redox balance between wildtype, Phe508del and knockout rat tissues, however when we looked at short term fluctuations in redox status using the ratio of the root mean squared of successive differences (RMSSD) to the normalised mean IVOS arbitrary units, we saw significantly elevated fluctuations in the redox status in the bronchi of Phe508del rats compared to wildtype rats, indicating a lower steady-state oxidative environment combined with large transient oxidative events.
Stroke is a major pathology, but current diagnostic methods are prone to misclassification with other neurological conditions, e.g., epilepsy or migraine, which delays proper treatment and carries a poorer prognosis. Development of accurate biomarkers to diagnose stroke events could decrease misidentification occurrence and promote appropriate, timely management. Lipid peroxidation products are generated under oxidative stress conditions and have previously been shown to increase in stroke patients. As the reference standard for lipid peroxidation, oxylipins could be biomarkers for acute ischemic cerebrovascular syndrome (AICS) events. Moreover, the ability to triage at-risk patients could expedite the necessary procedures required to conclusively diagnose AICS incidents. A label-free, in vivo oxidative status (IVOS) technology measuring carbonylation was also tested to determine efficacy as a point-of-care assessment tool. Potential AICS patients were independently clinically classified as transient ischaemic attack (TIA) or minor ischaemic stroke (grouped as AICS), or mimics per our published FAST-IT Protocol, including radiological assessment. Plasma oxylipins were quantified using liquid chromatography tandem mass spectrometry while carbonylation was determined with IVOS technology. Oxylipin and IVOS metrics from diagnostic groups were compared using respective, univariate linear regressions. Concentrations of 4(RS)-4-F4t-NeuroP fragment (oxylipin) and Mean Fluorescence (ARBU) detected by mass spectrometry or IVOS technology, respectively, were higher in AICS patients compared with mimics. This is the first study to investigate an early point-of-care assessment device combined with a panel of oxylipins to identify markers of oxidative stress associated with transient or minor ischemic stroke incidents to improve diagnostic differentiation of AICS patients from mimics.